Literature DB >> 2981876

The human receptor for T-cell growth factor. Evidence for variable post-translational processing, phosphorylation, sulfation, and the ability of precursor forms of the receptor to bind T-cell growth factor.

W J Leonard, J M Depper, M Krönke, R J Robb, T A Waldmann, W C Greene.   

Abstract

The T-cell growth factor (TCGF) receptor on phytohemagglutinin-activated normal peripheral blood T-cells is characterized as a glycoprotein with an apparent Mr = 55,000 that contains N-linked and O-linked carbohydrate with only approximately 33,000 daltons of peptide structure (p33) as evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. There are two N-linked glycosylated intermediate precursor forms (apparent Mr = 35,000 (p35) and 37,000 (p37]. This receptor differs from the TCGF receptor on HUT-102B2 cells (apparent Mr = 50,000) because of differences in post-translational processing. Experiments with the carboxylic ionophore monensin demonstrate blockade of the transition of the p35 and p37 receptor precursor forms to the mature receptor, presumably secondary to inhibition of Golgi-associated receptor processing. We identify the primary translation product of TCGF receptor mRNA as intermediate in size between the p33 and the p35/p37 forms. We further demonstrate that the p33, p35, and p37 precursor forms, but not the primary translation product, are all capable of binding TCGF. Thus, the removal of the signal peptide and/or conformational changes of the primary translation product are necessary for ligand binding; however, the extensive post-translational modifications are not. Lastly, we demonstrate that at least some TCGF receptors are phosphorylated and sulfated, and that TCGF receptors on phytohemagglutinin-activated normal T-cells are more heavily sulfated than those on HUT-102B2 cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981876

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

Review 2.  Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2007-01-11       Impact factor: 8.317

3.  Conversion of low-affinity interleukin 2 receptors to a high-affinity state following fusion of cell membranes.

Authors:  R J Robb
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Only high-affinity receptors for interleukin 2 mediate internalization of ligand.

Authors:  A M Weissman; J B Harford; P B Svetlik; W L Leonard; J M Depper; T A Waldmann; W C Greene; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Characterization of the bovine receptor(s) for interleukin-2.

Authors:  D C Siess; N S Magnuson; R Reeves
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

6.  Abnormal intracellular sorting of O-linked carbohydrate-deficient interleukin-2 receptors.

Authors:  K F Kozarsky; S M Call; S K Dower; M Krieger
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

7.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 8.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

9.  Interleukin 2 receptor gene expression in normal human T lymphocytes.

Authors:  W J Leonard; M Krönke; N J Peffer; J M Depper; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA.

Authors:  T S Elton; L D Dion; K L Bost; S Oparil; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.